Key result
New direct-acting influenza antivirals, including baloxavir marboxil, have advanced in clinical development, though knowledge gaps remain due to unpublished data and ongoing pivotal studies.
Why the study?
Multiple direct-acting influenza antivirals have been licensed or advanced in development, but few are licensed for severe or hospitalized influenza and many knowledge gaps remain.
This review highlights recent advances in influenza therapeutics, including new antiviral classes like baloxavir marboxil, while noting significant knowledge gaps and ongoing clinical research challenges.
May expand influenza antiviral options; leaves open key efficacy and resistance data from ongoing trials.
In the last few years, several new direct-acting influenza antivirals have been licensed, and others have advanced in clinical development. The increasing diversity of antiviral classes should allow an adequate public health response should a resistant virus to one agent or class widely circulate. One new antiviral, baloxavir marboxil, has been approved in the United States for treatment of influenza in those at high risk of developing influenza-related complications. Except for intravenous zanamivir in European Union countries, no antivirals have been licensed specifically for the indication of severe influenza or hospitalized influenza. This review addresses recent clinical developments involving selected polymerase inhibitors, neuraminidase inhibitors, antibody-based therapeutics, and host-directed therapies. There are many knowledge gaps for most of these agents because some data are not published and multiple pivotal studies are in progress at present. This review also considers important clinical research issues, including regulatory pathways, study designs, endpoints, and target populations encountered during the clinical development of novel therapeutics.
No takes yet. Share an insight, caveat, or question.
Beigel et al. (2020) conducted a review in Influenza. Influenza antivirals was evaluated. New direct-acting influenza antivirals, including baloxavir marboxil, have advanced in clinical development, though knowledge gaps remain due to unpublished data and ongoing pivotal studies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: